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Quantifying drug permeability across lipid membranes is crucial for drug development. In addition, 
reduced membrane permeability is a leading cause of antibiotic resistance in bacteria, and hence there 
is a need for new technologies that can quantify antibiotic transport across biological membranes. 
We recently developed an optofluidic assay that directly determines the permeability coefficient of 
autofluorescent drug molecules across lipid membranes. Using ultraviolet fluorescence microscopy, 
we directly track drug accumulation in giant lipid vesicles as they traverse a microfluidic device while 
exposed to the drug. Importantly, our measurement does not require the knowledge of the octanol 
partition coefficient of the drug – we directly determine the permeability coefficient for the specific 
drug-lipid system. In this work, we report measurements on a range of fluoroquinolone antibiotics and 
find that their pH dependent lipid permeability can span over two orders of magnitude. We describe 
various technical improvements for our assay, and provide a new graphical user interface for data 
analysis to make the technology easier to use for the wider community.
A reduction in cell permeability to antibiotics is known to be an important biochemical mechanism of drug 
resistance in bacteria1,2. This problem is particularly acute in the case of Gram-negative pathogens, whose double 
membrane cell envelope provides a formidable barrier to the cellular entry of hydrophilic drugs2. Therefore, the 
study of antibiotic diffusion across bacterial membranes is of fundamental importance, both for the development 
of new drugs as well as for improving the efficacy of existing antibiotics.
It is also critical to study the role of environmental factors on drug permeability. For example, the pH of the 
surrounding environment plays a major role on a drug’s ability to permeate a lipid membrane – at different pH 
values, the drug molecule can exist in different charge states, which changes its lipophilicity3,4. This is of particular 
importance while studying the passage of a drug capsule through the human digestive tract – the pH changes 
from highly acidic in the stomach (1.0–2.5) to more neutral values (6.5–7.5) in the intestine5. The microenviron-
ment around an infection site can thus greatly influence the effectiveness of a drug.
However, obtaining quantitative information about drug permeability into bacterial cells is difficult due to 
their small size, and also because changes in experimental conditions and techniques can lead to contrasting 
results6. Understanding the exact pathways of drug transport across the cell membrane is also difficult with living 
cells due to the lack of control over the system. However, it is known that the majority of drug transport occurs 
due to passive diffusion across the cell membrane7,8. We therefore use giant unilamellar vesicles (GUVs) as highly 
controlled lipid systems. GUVs are created by electro-formation and we thus have excellent control over their 
composition, facilitating the study of passive drug permeation in a highly specific manner.
Microfluidics offers a convenient platform by which drug transport studies can be performed in a high 
throughput manner. There are numerous microfluidic techniques to study drug transport across Caco-2 cells, 
which provide information about the intestinal absorption characteristics of a drug9–11. Other approaches have 
targeted the role of the endothelial barrier lining blood vessels in drug uptake, where microfluidics enables the 
study of drug permeability under effects such as fluid-flow induced shear stress12. In addition, lipid vesicles have 
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been used in microfluidic devices to study membrane transport, both through the lipid membrane and through 
protein nanopores inserted into the lipid membrane13–15. These methods typically involve immobilizing the vesi-
cles on chip and flowing in the drug; drug uptake into the vesicles is visualised using fluorescent reporters.
We previously developed an optofluidic assay where GUVs are mixed with an antibiotic using a T junction 
microfluidic chip, the chip being illuminated with ultraviolet (UV) light4. Under UV illumination, many antibi-
otic molecules are autofluorescent, and can thus be tracked in a label-free manner. By studying the increase in 
autofluorescence within the vesicles over time as they pass through the channel in the presence of the antibiotic, 
we can determine the permeability coefficient of the drug4. Importantly, the technique determines drug perme-
ability directly without requiring the measurement of the octanol partition coefficient. Until now, we have used 
this technique to study the pH dependence of the transport of norfloxacin, a fluoroquinolone antibiotic, across 
lipid membranes4. Fluoroquinolones are broad spectrum antibiotics that target intracellular processes catalysed 
by DNA topoisomerases. Fluoroquinolones thus disrupt the DNA supercoiling process and inhibit bacterial cell 
division16. We have also studied the dependence of norfloxacin transport on the lipid composition of the mem-
brane, and in particular investigated bilayers containing different types of lipid molecules commonly found in the 
cytoplasmic membrane of Escherichia coli17. Our technique also enables direct measurements of drug uptake in 
proteoliposomes containing the E. coli outer membrane protein OmpF in the membrane; we thus quantified the 
role of these porins in norfloxacin transport18.
It is important to note here that bulk permeability measurement techniques such as the parallel artificial 
membrane permeability assay (PAMPA) need to account for the effect of the unstirred water layer (UWL) on drug 
permeation19,20. This aqueous layer may range up to hundreds of microns in size, and this additional boundary 
layer may replace the lipid membrane as the rate limiting step for drug permeation7,19. In this layer, there exists a 
concentration gradient of the drug. In our vesicle based assay, however, we can directly observe the concentration 
of the drug surrounding the vesicles via the autofluorescence of the drug molecules. In our previously published 
work, we imaged the cross section of a vesicle suspended in a bath of norfloxacin in a confocal microscope; we 
found no evidence for a large (micron scale) UWL surrounding the vesicles4. Similar single vesicle fluorescence 
experiments were also previously performed to study the transport (or lack thereof) of indole and indole acetic 
acid across lipid vesicle membranes. In these experiments as well there was no evidence to suggest a large UWL 
surrounding the vesicles21.
This evidence does not rule out the possibility of having a nanoscale UWL around the vesicles. However, the 
effect of the UWL on drug permeation is expected to be a function of velocity22, and we have previously shown that 
the permeability coefficients measured in our assay are independent of vesicle velocity4. Finally, we have used our 
assay to study the role of lipid composition on drug transport; we observed that simply changing the lipid molecules 
in the vesicle membranes from DPhPC to DOPC changed drug permeability by over an order of magnitude17. Thus 
the lipid membrane appears to be the rate limiting step to drug permeation in our assay. Even if a nanoscale UWL 
does exist around the vesicles, its effect on drug permeation appears to be minimal, and may be neglected here.
In this paper, we performed measurements using phosphatidylcholine (PC) lipids, which stably and repro-
ducibly form vesicles via electroformation. Our goal was simply to extend our technique to the study of different 
fluoroquinolones; we have already studied the effect of lipid composition on drug transport17. We measure the 
permeability of enrofloxacin, pefloxacin and fleroxacin at three different physiologically relevant pH values, cor-
responding to different charge states of the drug molecules3. A comparison of these molecules with norfloxacin 
reveals differences in their lipid permeation capabilities that span over two orders of magnitude.
We approach the problem of drug uptake in bacteria from a reductionist perspective, and show that the study 
of even simple PC lipids can help us understand the significant permeation differences between these fluoro-
quinolones. Phosphatidylcholine is also an important constituent of the intestinal mucus layer23. Thus our meas-
urements might be applicable to the understanding of drug absorption in the intestine as well.
The technique can be extended to all fluorescent drugs/molecules, thus providing quantitative informa-
tion about the transport of these drugs across lipid bilayers with well controlled compositions. We also discuss 
improvements in the experimental procedure and present a more streamlined analysis script which should make 
the measurement technique more accessible to other researchers in the field.
Materials and Methods
The T junction microfluidic chips used in the experiments (shown schematically in Fig. 1a) were constructed using 
standard photo- and soft lithography techniques4,18,24. The chips are made of Sylgard 184 polydimethylsiloxane 
(PDMS, Dow Corning) using an elastomer : curing agent ratio of 9:1. The chips are designed such that two time 
points may be observed in the same field of view (60× magnification). We have constructed multiple designs with 
different lengths of the mixing channel, which enable us to observe the vesicles over different timescales. For fast 
permeation experiments (on the order of a few seconds), we used a chip design where the channel length from 
the T junction to the outlet reservoir was 28 mm18. For measurements where the permeation was found to be 
slower (minutes), we used a chip with a channel length of approximately 380 mm from the T junction to the outlet 
reservoir4. In our experiments, vesicles typically flow through the channel at speeds of around 1 mm/s. AutoCAD 
drawings of the different designs are available on request.
Unless otherwise stated, all chemicals were obtained from Sigma Aldrich. 5 mM phosphate buffers were 
used for experiments at pH 6, pH 7 and 5 mM acetic acid as the buffer at pH 5. 1,2-diphytanoyl-sn-glycero-3- 
phosphocholine (DPhPC, Avanti Polar Lipids) lipid vesicles were prepared in the respective buffers in the pres-
ence of 200 mM sucrose using a standard electroformation protocol as previously described4.
In the experiments, 2 mM solutions of the antibiotics were introduced at one of the inlets of the microfluidic 
chip, with the other inlet containing the vesicles. The antibiotic solutions were prepared in the relevant buffer/
sucrose solutions and the pH adjusted to desired values using HCl/KOH. Suction was applied at the outlet res-
ervoir to pull vesicles and antibiotic molecules into the mixing channel. As shown in the schematic (Fig. 1a), 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:32824 | DOI: 10.1038/srep32824
once past the T junction, the antibiotic molecules diffuse across the width of the channel. The vesicles thus pass 
through a bath of drug molecules, and as the drug diffuses across the vesicle membrane, the drug autofluores-
cence intensity within the vesicle increases. By studying this increase in autofluorescence within the vesicles over 
time, the permeability coefficient (P) of the drug across the lipid membrane can be extracted using the following 
equation4:
= −



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where R is the vesicle radius, t is the time taken for the vesicle to move from the initial (t = 0) to the final (t) detec-
tion point, and Δ I is the normalised drug autofluorescence intensity difference between the interior (Iin) and the 
exterior (Iout) of the vesicle:
∆ =
−I I I
I (2)
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As the drug permeates into the vesicle, Iin increases and hence Δ I decreases. Thus, the decrease in Δ I for the 
vesicles over time is a direct measure of drug permeation into the vesicles. The permeability equation above is 
designed to account for the fact that the experiment uses brightfield rather than confocal fluorescence micros-
copy. The consequences of such an experimental setup for the measurement of drug fluorescence within a vesicle 
are explained in detail in the ESI of ref. 4. In addition, we have provided comprehensive explanations of the 
assumptions inherent in the permeability calculation in the supplementary information attached with this paper.
The optofluidic assay is performed as follows:
•	 The PDMS chip is bonded to a glass coverslip (type I thickness, Assisstent) by a standard plasma bonding 
procedure using an air plasma (10 W, 25 sccm, 10 s exposure, Diener Electronic GmbH & Co. KG). The 
bonded chip is then left in an oven at 60 °C for 5–10 mins to enhance the adhesion. Following this, chips are 
immediately filled with buffer solution to wet the channels.
Figure 1. Schematic of the optofluidic assay. (a) Vesicles and antibiotic molecules are mixed using a T 
junction microfluidic chip. Under UV illumination, the antibiotic molecules are autofluorescent. The channel 
width is 40 μ m. Vesicles can be detected at two time points in the same field of view. As a vesicle traverses the 
channel, the drug permeates into the vesicle and hence the drug autofluorescence intensity within the vesicle 
increases. This increase in drug autofluorescence inside the vesicle (Iin) is used to determine the permeability 
coefficient of the drug across the vesicle lipid membrane on the basis of a simple diffusion model4. (b) Typical 
experimental data, depicting the permeation of pefloxacin into DPhPC lipid vesicles at pH 6. Each point in 
the scatter plot represents an individual vesicle. The dark grey squares refer to vesicles detected at the initial 
(t = 0) time point whereas the blue triangles refer to vesicles detected at the later detection point (on average 8.5 
s further downstream for this particular measurement). The downward shift in ΔI with time is a result of the 
increase in autofluorescence within the vesicles (Iin) and is thus a direct measurement of pefloxacin permeation 
into the vesicles. Similar scatter plots for the other drug/pH conditions measured in this paper are presented in 
the Supplementary Information. (c) Chemical structures of the fluoroquinolone antibiotics investigated in this 
paper arranged in order of decreasing octanol partition coefficients (Table 1).
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•	 A pipette tip containing 40 μ l of the antibiotic solution is inserted into one inlet column, and similarly a 
pipette tip containing 40 μ l of the vesicle solution is inserted into the other inlet column.
•	 Suction is applied at the outlet using a neMESYS syringe pump system with a 250 μ l Duran Borosilicate glass 
syringe connected to the chip using Upchurch 1520 G tubing.
•	 The chip, with its connections, is placed on the stage of a UV epifluorescence microscope containing a 60× 
objective. We performed most of the experiments described in this paper on a custom-built microscope4 with 
an excitation wavelength of 340 or 350 nm, selected using a monochromator (Oceanoptics Monoscan 2000); 
an EQ99FC (Energetiq) broadband white light source was used. However, we also performed experiments 
using a commercial Olympus IX73 microscope with a DAPI filter set (Chroma) and an arc lamp (Prior Lumen 
200) as the light source. There was no significant difference observed in the results with the different excita-
tion wavelengths, as expected; any standard DAPI fluorescence setup is therefore suitable for our technique.
•	 Initially, a high flow rate is applied (30–50 μ l/hr). Once the drug fluorescence intensity reaches its peak value 
in the channel, the flow rate is lowered to 3 μ l/hr.
•	 Once the flows stabilise, images are recorded at 100 fps. We used an Evolve 512 Delta EMCCD (Photometrics) 
or an optiMOS scientific CMOS camera (QImaging) in our experiments. Binning reduces the size of the data 
being acquired, averages over fluctuating pixels and optimises the frame rate. Images were recorded using 
μ Manager 1.425.
•	 The permeability coefficient of the drug is inferred from the increase in drug autofluorescence intensity 
within the vesicles over time4.
•	 Image analysis is performed using MATLAB scripts as described previously4,18. Briefly, vesicles are tracked 
for multiple frames, from which individual vesicle velocities can be calculated. Combined with a knowledge 
of the chip geometry, one can calculate the time (t) taken by each vesicle to move from the initial to the final 
detection position. The radius of a vesicle is calculated as the average of the semi-major and semi-minor axes 
of the detected shape. Iin is measured around the centre of the vesicle, and Iout is measured at the same location 
in the absence of the vesicle (basic versions of the MATLAB scripts used are freely available as part of the ESI 
of ref. 4). We have also developed a new MATLAB user interface for the final data analysis; this is described 
in the Supplementary Information document and the script is attached. A detailed description of the filters 
applied is also provided in the Supplementary Information.
Results and Discussion
Experiments were performed at pH 5, 6 and 7, corresponding to different charge states of the fluoroquinolones 
being investigated (Fig. 2). For all three drugs, significant lipid permeation was observed within the timescales 
investigated for all three pH values. At pH 6 and pH 7, enrofloxacin transport was so rapid that the second detec-
tion point had to be chosen less than a second away from the first detection point in the flow system; at later times 
the contrast between the vesicles and the background was too low for them to be detected using this technique, 
since our analysis detects vesicles based on their contrast with the background fluorescence. A similar level of 
transport was observed with pefloxacin at pH 7, as seen in the relevant scatter plots in Figures S4 and S6.
For all three drugs, we observed an increase in permeability coefficients as we increased the pH from 5 to 7. 
The permeability coefficients are provided in Table 1, and depicted visually in Fig. 3. Histograms of the permeabil-
ity coefficients (from all the experiments performed) are provided in Fig. 2 and in further detail in Supplementary 
Figure S7. In our earlier work we had measured the permeability of norfloxacin at pH 5 and 7; for completeness, 
we measured norfloxacin permeability at pH 6 as well (Supplementary Information Figure S3). At pH 5, the 
molecules are predominantly positively charged, whereas the proportion of zwitterionic/uncharged molecules is 
Figure 2. Histograms representing the measured permeability coefficients of fleroxacin, pefloxacin and 
enrofloxacin across DPhPC lipid vesicle membranes as a function of pH. The counts provided here are 
normalised to the total number of vesicles detected in each case, to enable direct comparison of the permeability 
coefficients across the different conditions. For all three fluoroquinolones, the permeability increases as we 
increase the pH from acidic (pH 5) to neutral values. The mean permeability coefficients are reported in 
Table 1. From the histograms, we observe that fleroxacin has the lowest permeability of the three drugs, and 
enrofloxacin the highest. Separate histograms and the experimental scatter plots for each condition are provided 
in the Supplementary Information.
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higher at pH 6 and 7. This explains the pH dependence of the permeability coefficients, since charged moieties are 
less lipophilic as they do not easily dissolve in the hydrocarbon core of the lipid bilayer.
The four molecules studied are all fluoroquinolone derivatives, but differ with respect to the structure of their 
chemical substituents. It is these subtle differences in the substituents that underpin the wide range of permeabil-
ity coefficients (Fig. 3). All four derivatives contain a piperazin-1-yl group at the C-7 position (see Supplementary 
Figure S2 for the general chemical structure). However, only in the norfloxacin molecule is the amine at the N-4 
position of the piperazin-1-yl group a secondary amine. In the other three molecules, these amines are tertiary 
and therefore their hydrophobicity is enhanced compared to norfloxacin26. This explains the lower lipid solubil-
ity of norfloxacin; it therefore has the lowest permeability value of the series. At the other end of the spectrum, 
enrofloxacin exhibits the largest permeability value. This compound possesses a 4-ethyl-piperazin-1-yl group 
at the C-7 position that confers more lipophilicity than the 4-methyl-piperazin-1-yl present in fleroxacin and 
pefloxacin, as evidenced by the corresponding octanol partition coefficients of the different molecules (Table 1). 
This derivative also contains a cyclopropyl group at N-1 whereas the other molecules contain an ethyl group at 
the same position. However, the difference in lipophilicity conferred by these two substituents at N-1 is reported 
to be less significant compared to the effect of increasing the hydrophobic character of the C-7 substituent26. It is 
therefore likely that the 4-ethyl-piperazin-1-yl C-7 substituent of enrofloxacin confers it with the highest perme-
ability value of the series.
Fleroxacin and pefloxacin were found to have similar permeability at pH 5, with the permeability of pefloxacin 
being higher at pH 6 and pH 7. Fleroxacin has two extra fluorine atoms compared to pefloxacin, one attached 
to the aromatic ring at C-8 and the other in the ethyl group at N-1. The fluorine atom on the aromatic ring is 
expected to increase the lipophilicity27, but the fluorine atom in the aliphatic group has been shown to produce 
the opposite effect28. The latter may be responsible for the reduced lipophilicity and hence the decreased perme-
ability value of fleroxacin. This also explains the higher octanol partition coefficient of pefloxacin compared to 
fleroxacin (Table 1).
Conclusions
In this paper we extended our optofluidic measurement technique to investigate differences in the permeability 
of four fluoroquinolones over a range of pH values. The results obtained are validated by considering the chem-
ical structures of the molecules; the permeability coefficients increase with an increase in the lipophilicity of the 
molecules, as expected. This technique can complement traditional drug transport assays such as the parallel 
Antibiotic pH 5 pH 6 pH 7
Literature Values of Apparent 
Octanol Partition Coefficients 
(log Kapp, mean ± s.d)
Enrofloxacin 8.8 ± 0.1 68 ± 3 124 ± 4 3.48 ± 0.04 (pH 7)32
Pefloxacin 4.11 ± 0.05 10.8 ± 0.2 52 ± 2 0.23 ± 0.05 (pH 7)33
Fleroxacin 4.1 ± 0.2 6.5 ± 0.1 11.0 ± 0.2 − 0.72 ± 0.18 (pH 7.4)34
Norfloxacin 0.1 0.122 ± 0.004 0.59 ± 0.02 − 1.00 ± 0.03 (pH 7)33
Table 1.  Permeability Coefficients (×10−6 cm/s, mean ± s.e).
Figure 3. Comparison of the permeability coefficients (P) for the four fluoroquinolones studied as a 
function of pH. The error bars (s.e.) are smaller than the symbol size. The permeability coefficient values for 
norfloxacin at pH 5 and 7 are taken from Ref. 4. For all the molecules, the permeability increases as we increase 
the pH from 5 to 7. We find large differences in the absolute values of the permeability coefficients between 
the drugs; the permeability of enrofloxacin is approximately two orders of magnitude greater than that of 
norfloxacin, across the pH range studied. Norfloxacin has the lowest permeability of the drugs studied, while 
enrofloxacin has the highest.
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artificial membrane permeability assay (PAMPA)29 as we directly measure the permeability coefficient of the 
drug across the lipid membrane of interest. Furthermore, unlike earlier techniques, we have shown that this 
assay can be used to study drug uptake through transporters18; the technique can thus be used to investigate drug 
transport across more realistic model membranes, containing different membrane proteins commonly found in 
bacterial cell membranes. To extend the technique to molecules that are not autofluorescent, reporter complexes 
that fluorescence upon binding to a drug molecule could be used; such fluorescent drug-reporter complexes have 
been studied previously in vesicles14. Finally, a number of new microfluidic vesicle preparation techniques are 
under development30,31. Such technologies could be combined with our assay to make the entire process, from 
vesicle production to drug testing, functional on a single microfluidic device. We believe that such developments 
will be of great benefit to all those interested in studying drug-membrane interactions in both the academic and 
pharmaceutical communities.
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